Agenus reports inducement grants under nasdaq listing rule 5635(c)(4)

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the compensation committee of agenus' board of directors granted inducement awards to nils eckardt, kent barnes, and brian greenblatt, in connection with their appointments as chief medical affairs officer, head of marketing and sales, and vice president commercial operations and business analytics, respectivel.
AGEN Ratings Summary
AGEN Quant Ranking